1 Study Coverage 1.1 Benign Prostatic Hyperplasia (BPH) Treatment Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Introduction 1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Outlook 2017 VS 2022 VS 2028 1.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size for the Year 2017-2028 1.2.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size for the Year 2017-2028 1.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Benign Prostatic Hyperplasia (BPH) Treatment in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Benign Prostatic Hyperplasia (BPH) Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Benign Prostatic Hyperplasia (BPH) Treatment Market Dynamics 1.4.1 Benign Prostatic Hyperplasia (BPH) Treatment Industry Trends 1.4.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers 1.4.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Challenges 1.4.4 Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Benign Prostatic Hyperplasia (BPH) Treatment by Type 2.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Segment by Type 2.1.1 Drugs 2.1.2 Devices 2.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2017, 2022 & 2028) 2.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2017-2028) 2.4 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2017, 2022 & 2028) 2.5 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2017-2028) 3 Benign Prostatic Hyperplasia (BPH) Treatment by Application 3.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Segment by Application 3.1.1 Hospitals 3.1.2 Clinics 3.1.3 Others 3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2017, 2022 & 2028) 3.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2017-2028) 3.4 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2017, 2022 & 2028) 3.5 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2017-2028) 4 Global Benign Prostatic Hyperplasia (BPH) Treatment Competitor Landscape by Company 4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Company 4.1.1 Top Global Benign Prostatic Hyperplasia (BPH) Treatment Companies Ranked by Revenue (2021) 4.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Player (2017-2022) 4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Concentration Ratio (CR) 4.2.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Benign Prostatic Hyperplasia (BPH) Treatment in 2021 4.2.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Headquarters, Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Type 4.3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Headquarters and Area Served 4.3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Companies Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Company 4.5.1 Top Benign Prostatic Hyperplasia (BPH) Treatment Players in United States, Ranked by Revenue (2021) 4.5.2 United States Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Players (2020, 2021 & 2022) 5 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region 5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2017-2028) 5.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region: 2017-2022 5.2.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth 2017-2028 6.1.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth 2017-2028 6.3.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth 2017-2028 6.4.2 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Pfizer 7.1.1 Pfizer Company Details 7.1.2 Pfizer Business Overview 7.1.3 Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.1.4 Pfizer Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.1.5 Pfizer Recent Development 7.2 Sanofi 7.2.1 Sanofi Company Details 7.2.2 Sanofi Business Overview 7.2.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.2.4 Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.2.5 Sanofi Recent Development 7.3 GlaxoSmithKline 7.3.1 GlaxoSmithKline Company Details 7.3.2 GlaxoSmithKline Business Overview 7.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.3.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.3.5 GlaxoSmithKline Recent Development 7.4 Boston Scientific 7.4.1 Boston Scientific Company Details 7.4.2 Boston Scientific Business Overview 7.4.3 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.4.4 Boston Scientific Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.4.5 Boston Scientific Recent Development 7.5 Teleflex 7.5.1 Teleflex Company Details 7.5.2 Teleflex Business Overview 7.5.3 Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.5.4 Teleflex Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.5.5 Teleflex Recent Development 7.6 Cardinal Health 7.6.1 Cardinal Health Company Details 7.6.2 Cardinal Health Business Overview 7.6.3 Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.6.4 Cardinal Health Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.6.5 Cardinal Health Recent Development 7.7 Allergan 7.7.1 Allergan Company Details 7.7.2 Allergan Business Overview 7.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.7.4 Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.7.5 Allergan Recent Development 7.8 Teva Pharmaceutical 7.8.1 Teva Pharmaceutical Company Details 7.8.2 Teva Pharmaceutical Business Overview 7.8.3 Teva Pharmaceutical Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.8.4 Teva Pharmaceutical Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.8.5 Teva Pharmaceutical Recent Development 7.9 Mylan 7.9.1 Mylan Company Details 7.9.2 Mylan Business Overview 7.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.9.4 Mylan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.9.5 Mylan Recent Development 7.10 Eli Lilly 7.10.1 Eli Lilly Company Details 7.10.2 Eli Lilly Business Overview 7.10.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Introduction 7.10.4 Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) 7.10.5 Eli Lilly Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Benign Prostatic Hyperplasia (BPH) Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Benign Prostatic Hyperplasia (BPH) Treatment Market Trends Table 3. Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers Table 4. Benign Prostatic Hyperplasia (BPH) Treatment Market Challenges Table 5. Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints Table 6. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Benign Prostatic Hyperplasia (BPH) Treatment Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Share by Player, 2017-2022 Table 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Benign Prostatic Hyperplasia (BPH) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2021) Table 15. Top Players of Benign Prostatic Hyperplasia (BPH) Treatment in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Benign Prostatic Hyperplasia (BPH) Treatment Players in United States Market, Ranking by Revenue (2021) Table 20. United States Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Benign Prostatic Hyperplasia (BPH) Treatment Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Benign Prostatic Hyperplasia (BPH) Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Benign Prostatic Hyperplasia (BPH) Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Benign Prostatic Hyperplasia (BPH) Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Pfizer Company Details Table 31. Pfizer Business Overview Table 32. Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Product Table 33. Pfizer Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 34. Pfizer Recent Development Table 35. Sanofi Company Details Table 36. Sanofi Business Overview Table 37. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product Table 38. Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 39. Sanofi Recent Development Table 40. GlaxoSmithKline Company Details Table 41. GlaxoSmithKline Business Overview Table 42. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product Table 43. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 44. GlaxoSmithKline Recent Development Table 45. Boston Scientific Company Details Table 46. Boston Scientific Business Overview Table 47. Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Product Table 48. Boston Scientific Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 49. Boston Scientific Recent Development Table 50. Teleflex Company Details Table 51. Teleflex Business Overview Table 52. Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Product Table 53. Teleflex Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 54. Teleflex Recent Development Table 55. Cardinal Health Company Details Table 56. Cardinal Health Business Overview Table 57. Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Product Table 58. Cardinal Health Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 59. Cardinal Health Recent Development Table 60. Allergan Company Details Table 61. Allergan Business Overview Table 62. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product Table 63. Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 64. Allergan Recent Development Table 65. Teva Pharmaceutical Company Details Table 66. Teva Pharmaceutical Business Overview Table 67. Teva Pharmaceutical Benign Prostatic Hyperplasia (BPH) Treatment Product Table 68. Teva Pharmaceutical Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 69. Teva Pharmaceutical Recent Development Table 70. Mylan Company Details Table 71. Mylan Business Overview Table 72. Mylan Benign Prostatic Hyperplasia (BPH) Treatment Product Table 73. Mylan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 74. Mylan Recent Development Table 75. Eli Lilly Company Details Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product Table 78. Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) & (US$ Million) Table 79. Eli Lilly Recent Development Table 80. Research Programs/Design for This Report Table 81. Key Data Information from Secondary Sources Table 82. Key Data Information from Primary Sources List of Figures Figure 1. Benign Prostatic Hyperplasia (BPH) Treatment Product Picture Figure 2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2017-2028 (US$ Million) Figure 4. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2017-2028 (US$ Million) Figure 6. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share in Global 2017-2028 Figure 7. Benign Prostatic Hyperplasia (BPH) Treatment Report Years Considered Figure 8. Product Picture of Drugs Figure 9. Product Picture of Devices Figure 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type in 2022 & 2028 Figure 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2017-2028) & (US$ Million) Figure 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2017-2028) Figure 13. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type in 2022 & 2028 Figure 14. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2017-2028) & (US$ Million) Figure 15. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2017-2028) Figure 16. Product Picture of Hospitals Figure 17. Product Picture of Clinics Figure 18. Product Picture of Others Figure 19. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application in 2022 & 2028 Figure 20. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2017-2028) & (US$ Million) Figure 21. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2017-2028) Figure 22. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application in 2022 & 2028 Figure 23. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2017-2028) & (US$ Million) Figure 24. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2017-2028) Figure 25. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 26. U.S. Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 27. Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 28. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 29. Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 30. France Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. U.K. Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 35. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. Taiwan Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Thailand Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 46. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 50. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. U.A.E Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 54. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 55. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 56. Boston Scientific Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 57. Teleflex Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 58. Cardinal Health Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 59. Allergan Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 60. Teva Pharmaceutical Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 61. Mylan Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 62. Eli Lilly Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2017-2022) Figure 63. Bottom-up and Top-down Approaches for This Report Figure 64. Data Triangulation Figure 65. Key Executives Interviewed

Pfizer Sanofi GlaxoSmithKline Boston Scientific Teleflex Cardinal Health Allergan Teva Pharmaceutical Mylan Eli Lilly